(R)-Hydroxy-O-ethyl Des(boric Acid) Bortezomib is an intermediate in the synthesis of (S)-Hydroperoxy Des(boric Acid) Bortezomib, which is an impurity of Bortezomib, the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer.